AIFA Agenzia Italiana del Farmaco
List of innovative drugs
AIFA publishes the October 2022 update
AIFA updates the list of medicines that, in the opinion of the Technical Scientific Commission, meet the requirement of full or conditional therapeutic innovativeness.
The list represents the innovative products that must be made immediately available to patients, even without formal inclusion in regional hospital therapeutic handbooks.
The reference to the inclusion in the list is published in the Official Journal for each individual specialty in relation to the indication in the SSN reimbursement system.This list also includes the details of the products that have access to the fund for innovative oncology and non-oncology drugs (art. 1, paragraphs 402, 403 and 404, of the law of 11 December 2016, n. 232 and subsequent amendments).
In addition to the above reports, AIFA publishes reports on medicinal products that have had a negative outcome in the evaluation for the purposes of innovativeness:
BRUKINSA (zanubrutinib) indicated, as monotherapy, for the treatment of adult patients with Waldenström macroglobulinemia (WM) who have received at least one previous therapy, or as first-line treatment for patients unsuitable for chemo-immunotherapy
KYPROLIS (carfilzomib) indicated, in combination with daratumumab and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Published on:
To download the document go to the following AIFA Link:
https://www.aifa.gov.it/farmaci-innovativi
— Reproduction reserved and for personal use
Access to the site is limited and reserved for healthcare professionals
You have reached the maximum number of visits
Source — https://www.univadis.it/viewarticle/elenco-dei-farmaci-innovativi